CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ong, B. C.
Right arrow Articles by Burrows, F. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ong, B. C.
Right arrow Articles by Burrows, F. A.

Canadian Journal of Anesthesia, Vol 45, 1176-1180, Copyright © 1998 by Canadian Anesthesiologists' Society

ARTICLES

Prevalence of factor V Leiden in a population of patients with congenital heart disease

BC Ong, AA Zimmerman, DC Zappulla, EJ Neufeld and FA Burrows
Department of Anaesthesia, Children Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.

PURPOSE: The incidence of thrombotic events following cardiopulmonary bypass (CPB) in patients receiving surgical repair or palliation of congenital heart defects (CHD) is as high as 16%. Protein C, an intrinsic anticoagulation protease which, when activated, breaks down factor Va of the coagulation system, aids in maintaining a normal procoagulant/anticoagulant balance. Resistance of factor Va to degradation by activated protein C occurs and predisposes to thrombotic events. The resistance of factor Va to such degradation is, in the majority of cases, due to a genetic mutation referred to as factor V Leiden (FVLeiden). The presence of FVLeiden can be diagnosed using a DNA based assay. The prevalence of FVLeiden in the with CHD has not been determined. The objective of this study was to determine the prevalence of FVLeiden in patients with CHD. METHODS: Two hundred consecutive patients with CHD undergoing surgical repair or palliation requiring cardiopulmonary bypass were studied. Blood was taken before administration of homologous blood transfusion and assayed using a DNA based method with polymerase chain reaction amplification for the FVLeiden mutation. RESULTS: The prevalence of FVLeiden in our study population was 9/200 (4.5%). None of these patients demonstrated thrombotic complications. However, three patients (1.5%) without the FVLeiden mutation developed postoperative thrombotic complications. CONCLUSIONS: The prevalence of FVLeiden in patients is 4.5% that is not different from that of the population at large. There was no identifiable association with the occurrence of postoperative thrombotic events.


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
B. S. Donahue
The Response to Activated Protein C After Cardiopulmonary Bypass: Impact of Factor V Leiden
Anesth. Analg., December 1, 2004; 99(6): 1598 - 1603.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
B. S. Donahue
Factor V Leiden and Perioperative Risk
Anesth. Analg., June 1, 2004; 98(6): 1623 - 1634.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
B. S. Donahue, D. Gailani, M. S. Higgins, D. C. Drinkwater, and A. L. George Jr
Factor V Leiden Protects Against Blood Loss and Transfusion After Cardiac Surgery
Circulation, February 25, 2003; 107(7): 1003 - 1008.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. Monagle, A. D. Michelson, E. Bovill, and M. Andrew
Antithrombotic Therapy in Children
Chest, January 1, 2001; 119(1_suppl): 344S - 370S.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the Canadian Anesthesiologists' Society.